2460P Patient-reported outcomes in a randomised phase I study of mevrometostat (M) plus enzalutamide (E) vs E alone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Year: 2025
Type: article
Source: Annals of Oncology
Authors: M. Schweizer, M. Calvo, V. Moreno Garcia, B. Mellado Gonzalez, D.E. Castellano Gauna, A.I. Spira, Q. Wei, J. Carles Galceran, B. Garmezy, C. Kwak, I. Lugowska, K.D. Penkov, N.D. Shore, J. Tougias, C. Andreu-Vieyra, N. Soman, A. Niyazov, T. Alonso Gordoa
Institutions: University of Washington, Fred Hutch Cancer Center, Institut Català d'Oncologia, Hospital Universitario Fundación Jiménez Díaz, Hospital Clínic de Barcelona, Hospital Universitario 12 De Octubre, Virginia Cancer Specialists, West China Hospital of Sichuan University, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Sarah Cannon, Seoul National University, Seoul National University Hospital, The Maria Sklodowska-Curie National Research Institute of Oncology, Carolina Urologic Research Center, Pfizer (United States), Hospital Universitario Ramón y Cajal
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: Pfizer
OpenAlex ID: W4415939866
FWCI:
Cites:
Cited by:
Related to: